MedTrace Logo

Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis

NCT07674134 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2026-06-29

No results posted yet for this study

Summary

The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response.

The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.

Conditions

  • Rheumatoid Arthritis (RA)

Sponsors & Collaborators

  • Centre Hospitalier Princesse Grace

    lead OTHER

Principal Investigators

  • Olivier BROCQ, MD · Centre Hospitalier Princesse Grace

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-23
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • Monaco

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07674134 on ClinicalTrials.gov